| Skyline Ridge Nursing And Rehabilitation Center | |
| 515 Fairview St, Canon City, Colorado 81212 | |
| (719) 275-0665 | |
| Name | Skyline Ridge Nursing And Rehabilitation Center |
|---|---|
| Location | 515 Fairview St, Canon City, Colorado |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 85 |
| Occupancy Rate | 77.06% |
| Medicare ID (CCN) | 065250 |
| Legal Business Name | Snh Co Tenant Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1255386546 |
| Organization Name | FIVE STAR QUALITY CARE-COLORADO LLC |
| Doing Business As | SKYLINE RIDGE APARTMENTS AND NURSING & REHABILITATION CENTER |
| Address | 515 Fairview Ave, Canon City, CO 81212 |
| Phone Number | 719-275-0665 |
News Archive
Health care workers with high resilience or strong emotional support were protected against the effects of stress related to the COVID-19 pandemic compared to those who had low emotional support or resilience, according to a study published September 13 in the Journal of Medical Internet Research.
Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, recently sponsored a Satellite Symposium at the World Meeting of Melanoma/Skin Cancer Centers in Berlin, Germany. The session, titled "Regional Therapeutic Options for Metastatic Melanoma," was held on Friday, November 20 and featured updates and observations on a variety of current therapies by clinical leaders in the field.
Diversionary Therapy Technologies (DTT) is pleased to announce the release of ditto dental, an interactive electronic device containing augmented reality content to prepare children for dental procedures, resulting in reduced stress and anxiety for the pediatric patient and increased clinical productivity.
A diagnosis of pancreatic cancer—the fourth most common cause of cancer death in the U.S.—can be devastating. Due in part to aggressive cell replication and tumor growth, pancreatic cancer progresses quickly and has a low five-year survival rate (less than 5 percent).
Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF).
› Verified 9 days ago
| NPI Number | 1497134456 |
| Organization Name | DIVERSICARE OF CANON CITY, LLC |
| Doing Business As | DIVERSICARE OF CANON CITY |
| Address | 515 Fairview Ave, Canon City, CO 81212 |
| Phone Number | 719-275-0665 |
News Archive
Health care workers with high resilience or strong emotional support were protected against the effects of stress related to the COVID-19 pandemic compared to those who had low emotional support or resilience, according to a study published September 13 in the Journal of Medical Internet Research.
Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, recently sponsored a Satellite Symposium at the World Meeting of Melanoma/Skin Cancer Centers in Berlin, Germany. The session, titled "Regional Therapeutic Options for Metastatic Melanoma," was held on Friday, November 20 and featured updates and observations on a variety of current therapies by clinical leaders in the field.
Diversionary Therapy Technologies (DTT) is pleased to announce the release of ditto dental, an interactive electronic device containing augmented reality content to prepare children for dental procedures, resulting in reduced stress and anxiety for the pediatric patient and increased clinical productivity.
A diagnosis of pancreatic cancer—the fourth most common cause of cancer death in the U.S.—can be devastating. Due in part to aggressive cell replication and tumor growth, pancreatic cancer progresses quickly and has a low five-year survival rate (less than 5 percent).
Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF).
› Verified 9 days ago
| NPI Number | 1861034209 |
| Organization Name | CANON CITY NURSING AND REHAB CENTER, LLC |
| Address | 515 Fairview Ave, Canon City, CO 81212 |
| Phone Number | 801-601-1450 |
News Archive
Health care workers with high resilience or strong emotional support were protected against the effects of stress related to the COVID-19 pandemic compared to those who had low emotional support or resilience, according to a study published September 13 in the Journal of Medical Internet Research.
Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, recently sponsored a Satellite Symposium at the World Meeting of Melanoma/Skin Cancer Centers in Berlin, Germany. The session, titled "Regional Therapeutic Options for Metastatic Melanoma," was held on Friday, November 20 and featured updates and observations on a variety of current therapies by clinical leaders in the field.
Diversionary Therapy Technologies (DTT) is pleased to announce the release of ditto dental, an interactive electronic device containing augmented reality content to prepare children for dental procedures, resulting in reduced stress and anxiety for the pediatric patient and increased clinical productivity.
A diagnosis of pancreatic cancer—the fourth most common cause of cancer death in the U.S.—can be devastating. Due in part to aggressive cell replication and tumor growth, pancreatic cancer progresses quickly and has a low five-year survival rate (less than 5 percent).
Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF).
› Verified 9 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Health care workers with high resilience or strong emotional support were protected against the effects of stress related to the COVID-19 pandemic compared to those who had low emotional support or resilience, according to a study published September 13 in the Journal of Medical Internet Research.
Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, recently sponsored a Satellite Symposium at the World Meeting of Melanoma/Skin Cancer Centers in Berlin, Germany. The session, titled "Regional Therapeutic Options for Metastatic Melanoma," was held on Friday, November 20 and featured updates and observations on a variety of current therapies by clinical leaders in the field.
Diversionary Therapy Technologies (DTT) is pleased to announce the release of ditto dental, an interactive electronic device containing augmented reality content to prepare children for dental procedures, resulting in reduced stress and anxiety for the pediatric patient and increased clinical productivity.
A diagnosis of pancreatic cancer—the fourth most common cause of cancer death in the U.S.—can be devastating. Due in part to aggressive cell replication and tumor growth, pancreatic cancer progresses quickly and has a low five-year survival rate (less than 5 percent).
Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF).
› Verified 9 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $3250 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 13.43 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 12.74 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 44.76 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.45 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.23 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0.7 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4.23 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 22.01 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 96.67 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.59 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 17.52 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 6.93 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 2.1 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.03 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 83.15 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 91.24 | 82.93 |
News Archive
Health care workers with high resilience or strong emotional support were protected against the effects of stress related to the COVID-19 pandemic compared to those who had low emotional support or resilience, according to a study published September 13 in the Journal of Medical Internet Research.
Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, recently sponsored a Satellite Symposium at the World Meeting of Melanoma/Skin Cancer Centers in Berlin, Germany. The session, titled "Regional Therapeutic Options for Metastatic Melanoma," was held on Friday, November 20 and featured updates and observations on a variety of current therapies by clinical leaders in the field.
Diversionary Therapy Technologies (DTT) is pleased to announce the release of ditto dental, an interactive electronic device containing augmented reality content to prepare children for dental procedures, resulting in reduced stress and anxiety for the pediatric patient and increased clinical productivity.
A diagnosis of pancreatic cancer—the fourth most common cause of cancer death in the U.S.—can be devastating. Due in part to aggressive cell replication and tumor growth, pancreatic cancer progresses quickly and has a low five-year survival rate (less than 5 percent).
Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an inhaled anti-infective to treat fungal infections associated with cystic fibrosis (CF).
› Verified 9 days ago
Centura Health Progressive Care Center Location: 1338 Phay Ave, Canon City, Colorado 81212 Phone: (719) 245-1406 | |
Skyline Ridge Nursing And Rehabilitation Center Location: 515 Fairview St, Canon City, Colorado 81212 Phone: (719) 275-0665 | |
Valley View Health Care Center, Inc Location: 2120 N 10th St, Canon City, Colorado 81212 Phone: (719) 275-7569 |